Abstract: The invention relates to medicine and pharmacology, more particularly to drugs, and even more particularly to pharmaceutical compositions for treating gastroesophageal reflux disease (GERD). The pharmaceutical composition for treating GERD contains at least one proton pump inhibitor (PPI) and at least one prebiotic. Also claimed is a method for treating gastroesophageal reflux disease in which it is not necessary to eradicate the presence of H. pylori in order to prevent the risks associated with the translocation of said bacteria from the antrum to the body of the stomach. The composition provides for prevention of the translocation of H. pylori by means of the colonization of the antrum by lactobacilli and the concurrent inhibition of H. pylori during PPI therapy. This makes it possible to dispense with the need to detect the bacteria and carry out a course of eradication therapy. The safety of long-term PPI therapy is increased.

Abstract: The invention relates to medicine and pharmacology, more particularly to drugs, and even more particularly to pharmaceutical compositions for treating gastroesophageal reflux disease (GERD). The pharmaceutical composition for treating GERD contains at least one proton pump inhibitor (PPI) and at least one prebiotic. Also claimed is a method for treating gastroesophageal reflux disease in which it is not necessary to eradicate the presence of H. pylori in order to prevent the risks associated with the translocation of said bacteria from the antrum to the body of the stomach. The composition provides for prevention of the translocation of H. pylori by means of the colonization of the antrum by lactobacilli and the concurrent inhibition of H. pylori during PPI therapy. This makes it possible to dispense with the need to detect the bacteria and carry out a course of eradication therapy. The safety of long-term PPI therapy is increased.